Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

BACKGROUND: Studies using novel antiandrogens (NAA) in patients with metastatic castration-resistant prostate cancer (mCRPC) have shown overall survival benefit. As patients develop resistance to NAA therapy, the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib in combination with NAA may beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiangyu, Pan, Yang, Wang, Qihua, Ren, Congzhe, Li, Muwei, Hao, Xuexue, Xie, Lijun, Liu, Xiaoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644304/
https://www.ncbi.nlm.nih.gov/pubmed/38027160
http://dx.doi.org/10.3389/fendo.2023.1225033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644304/
https://www.ncbi.nlm.nih.gov/pubmed/38027160
http://dx.doi.org/10.3389/fendo.2023.1225033

Ejemplares similares